oxophenylarsine has been researched along with cyclin d1 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hayash, H; Horii, T; Kitamura, K; Kobayashi, M; Maekawa, M; Naito, K; Nakamura, S; Naoe, T; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A | 1 |
1 other study(ies) available for oxophenylarsine and cyclin d1
Article | Year |
---|---|
Phenylarsine oxide (PAO) more intensely induces apoptosis in acute promyelocytic leukemia and As2O3-resistant APL cell lines than As2O3 by activating the mitochondrial pathway.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2004 |